DAVID SIDRANSKY, M.D.
Medical Practice at Rutland Ave, Baltimore, MD

7332590, Feb 19, 2008

Aug 16, 2002

10/486844

Mariana Nacht - Belmont MA, US
Tatiana Dracheva - Rockville MD, US
David Sidransky - Baltimore MD, US
Stephen Madden - Sudbury MA, US
Jin Jen - Brookeville MD, US

The United States of America as Represented by the Department of Health and Human Services - Washington DC
Genzyme Corporation - Cambridge MA
The Johns Hopkins University of Medicine - Baltimore MD

C07H 21/02, C12Q 1/68, C01D 15/08

536 231, 435 6, 435 912, 424 91

We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation. The messages of two p53-regulated genes, p21and 14-3-3σ, were consistently under-expressed in the adenocarcinomas, suggesting that the p53 pathway itself might be compromised in this cancer type. Gene expression observed by SAGE were consistent with the results obtained by quantitative real-time PCR or cDNA array analyses using 43 additional lung tumor and normal samples.

7846667, Dec 7, 2010

Aug 20, 2009

12/545028

Jin Jen - Baltimore MD, US
Gary A. Beaudry - Montclair NJ, US
Stephen L. Madden - Sudbury MA, US
Arthur H. Bertlesen - Ridgewood NJ, US
David Sidransky - Baltimore MD, US

Genzyme Corporation - Framingham MA
Johns Hopkins University - Baltimore MD

C12Q 1/68

435 6, 435 71, 536 235, 536 2431, 536 2433, 530350, 5303871, 5303877, 436 64

The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.

2013003, Feb 7, 2013

Feb 29, 2012

13/408338

David Sidransky - Baltimore MD, US

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

C12Q 1/68, A61B 1/00, C40B 30/04

506 9, 435 611, 600101

The present invention provides methods of determination of a global DNA methylation index (GDMI) in a sample from a subject, using a variety of methods which can detect global, genome-wide, and gene-specific DNA methylation to create methylation portraits that can be used for early detection, diagnosis, and clinical management in the personalized medicine space. Further, the invention provides methods of diagnosis of cancer, including gastric cancer and hepatocellular cancer in a subject, by comparing the GDMI in a sample obtained from a subject to the methylation index of standard controls. These methods allow diagnosis of gastric carcinoma and liver cancer in patients who may be asymptomatic or have inconclusive pathology, and allowing earlier treatment of the subject.

2010003, Feb 11, 2010

Apr 17, 2006

11/887418

Wim Van Criekinge - Sart-Tilman (Liege), BE
Josef Straub - Sart-Tilman (Liege), BE
David Sidransky - Baltimore MD, US

Oncomethylome Sciences, S.A. - Liege
The Johns Hopkins University - Baltimore MD

A61K 31/7088, C12Q 1/68, A61K 31/70, A61K 31/24, A61K 31/195, C12N 5/02, A61K 31/351, A61P 35/04

514 44 R, 435 6, 514 49, 514535, 514561, 435375, 514459

Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.

2005009, May 5, 2005

Aug 13, 2004

10/917330

David Sidransky - Baltimore MD, US

The Johns Hopkins University School of Medical - Baltimore MD

C12Q001/68

435006000

The present invention relates to the detection of a cell proliferative disorder associated with alterations of microsatellite DNA in a sample. The microsatellite DNA can be contained within any of a variety of samples, such as urine, sputum, bile, stool, cervical tissue, saliva, tears, or cerebral spinal fluid. The invention is a method to detect an allelic imbalance by assaying microsatellite DNA. Allelic imbalance is detected by observing an abnormality in an allele, such as an increase or decrease in microsatellite DNA which is at or corresponds to an allele. An increase can be detected as the appearance of a new allele. In practicing the invention, DNA amplification methods, particularly polymerase chain reactions, are useful for amplifying the DNA. DNA analysis methods can be used to detect such a decrease or increase. The invention is also a method to detect genetic instability of microsatellite DNA. Genetic instability is detected by observing an amplification or deletion of the small, tandem repeat DNA sequences in the microsatellite DNA which is at or corresponds to an allele. The invention is also a kit for practicing these methods.

6025127, Feb 15, 2000

Jan 14, 1994

8/181664

David Sidransky - Baltimore MD

The Johns Hopkins University School of Medicine - Baltimore MD

C12Q 168

435 6

Methods are provided for detection of target neoplastic nucleic acids in a tissue specimen, including a tumor margin or lymph node, and reagents therefor, wherein the nucleic acids are preferably mutant tumor suppressor genes or proto oncogenes. Methods for treatment of cell proliferative diseases utilizing ribozymes or antisense oligonucleotides specific for the target mutant nucleic acids and/or replacement wild type genes are also disclosed.

2005019, Sep 8, 2005

Nov 12, 2004

10/986161

David Sidransky - Baltimore MD, US
Li Mao - Houston TX, US
Hening Ren - Houston TX, US

C12Q001/68, G06F019/00, G01N033/48, G01N033/50

435006000, 702020000

Cancer screening models based on analysis of mass spectroscopy data can be used to predict upper aerodigestive tract cancer, including lung and head and neck cancers. Models can be generated by comparing spectral weight values obtained from upper aerodigestive tract cancer patients and from patients at high risk for such cancer. Predictor or covariate values identify spectral weight values associated with upper aerodigestive tract cancer.

5935787, Aug 10, 1999

May 12, 1997

8/854727

David Sidransky - Baltimore MD

The Johns Hopkins University - Baltimore MD

C12Q 168, C12P 1934, C07H 2104, C07H 2102

435 6

An assay for detection of a mammalian cell proliferative disorder associated with a hypermutable nucleic acid sequences is provided. The identification of particular hypermutable sequences such as microsatellite loci correlates with a particular cancer, thereby allowing detection of both primary tumors and metastatic sites within a patient.

7319023, Jan 15, 2008

Nov 8, 2002

10/290473

David Sidransky - Baltimore MD, US

The Johns Hopkins University - Baltimore MD

C12P 19/34, C12Q 1/68, C07H 21/04

435 912, 435 6, 4352872, 536 231, 536 235, 536 2431

An assay for detection of a mammalian cell proliferative disorder associated with a hypermutable nucleic acid sequences is provided. The identification of particular hypermutable sequences such as microsatellite loci correlates with a particular cancer, thereby allowing detection of both primary tumors and metastatic sites within a patient.